Moderna is the first American producer of the vaccine against coronavirus who tests its drug on babies. The company plans to involve 6,750 children in the U.S. and Canada.
The vaccination of children is considered critically important to reach the level of collective immunity that can stop the pandemic. However, the risk of serios infection among children is lower than that among adults. But the risk to pass the virus is still there, especially among the teenagers.
"This paediatric study will help us assess the potential safety and immunogenicity of our Covid-19 vaccine in this younger age population," said Moderna CEO Stéphane Bancel.